Botulinum toxin type A for controlling bruxism assessed with computerized occlusal analysis: A pilot study.

: To assess botulinum toxin-A (BTX-A) on mandibular movements and bite force (BF%) in bruxism.: Ten bruxers were divided into 2 groups based on BF% imbalance (G1: >10%, G2: <10%). BTX-A 140U was total injected into the masseter and temporalis muscles. A T-Scan® recorded BF%, occlusion time (OT), right, left, and protrusive disclusion time (DT) before administering BTX-A, as well as 15, 45, 90, and 120 days after injection.: The Friedman and Wilcoxon tests found significant differences in BF% in G1 subjects at 15 days ( = 0.028 s), OT at 90 ( = 0.043 s), and 120 ( = 0.027 s) days, DTR at 90 ( = 0.046 s) and 120 ( = 0.028 s) days, DTL at 15 ( = 0.043 s) and 90 ( = 0.027 s) days, and DTP 4590 days ( = 0.043 s).: BTX-A induced BF% starting at 15 days post-injection and influenced lateralities later.